How GLP-1 Drugs Reshape Your Gut Bacteria: A Systematic Review of 38 Studies

PRISMA-guided systematic review searching for studies on the effects of GLP-1 analogues on gut microbiota composition, richness, and abundance. Both animal and human studies were included. Thirty-eight studies met inclusion criteria. Results were synthesized narratively by drug type.

The gut microbiome influences metabolism, inflammation, appetite, and even brain function. Understanding how GLP-1 drugs alter gut bacteria could reveal new mechanisms explaining their broad health benefits — from weight loss to cardiovascular protection. It could also help predict which patients will respond best and guide microbiome-targeted combination therapies.

The gut microbiome has emerged as a key mediator of metabolic health, and the finding that GLP-1 drugs reshape it adds a new dimension to understanding these medications. Akkermansia muciniphila, which increased with both dulaglutide and semaglutide, is one of the most studied 'next-generation probiotics' and is associated with improved insulin sensitivity, reduced inflammation, and better gut barrier function. If GLP-1 drugs achieve some of their benefits by promoting Akkermansia and other beneficial bacteria, this could open the door to microbiome-targeted combination therapies.

Results varied considerably between studies due to differences in study populations, drug doses, treatment durations, and microbiome analysis methods. Most human studies were small. The systematic review synthesized results narratively rather than through meta-analysis, limiting quantitative conclusions. It remains unclear whether microbiome changes are a cause or consequence of the metabolic improvements from GLP-1 drugs. Animal model findings may not directly translate to human microbiome responses.